Nicholas E. Papadopoulos

3.5k total citations
82 papers, 2.4k citations indexed

About

Nicholas E. Papadopoulos is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicholas E. Papadopoulos has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 33 papers in Molecular Biology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicholas E. Papadopoulos's work include Cutaneous Melanoma Detection and Management (26 papers), Melanoma and MAPK Pathways (23 papers) and Immunotherapy and Immune Responses (14 papers). Nicholas E. Papadopoulos is often cited by papers focused on Cutaneous Melanoma Detection and Management (26 papers), Melanoma and MAPK Pathways (23 papers) and Immunotherapy and Immune Responses (14 papers). Nicholas E. Papadopoulos collaborates with scholars based in United States, Australia and Greece. Nicholas E. Papadopoulos's co-authors include Agop Y. Bedikian, Carl Plager, Robert S. Benjamin, Kevin B. Kim, Shreyaskumar Patel, Omar Eton, Sigrid Ring, Wen-Jen Hwu, Patrick Hwu and Antônio C. Buzaid and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Nicholas E. Papadopoulos

81 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicholas E. Papadopoulos United States 28 1.4k 870 706 484 286 82 2.4k
Mustafa Beneklı Türkiye 24 1.2k 0.8× 623 0.7× 601 0.9× 291 0.6× 303 1.1× 182 2.6k
James D. Reimann United States 12 967 0.7× 607 0.7× 813 1.2× 340 0.7× 209 0.7× 16 3.0k
Mrinal M. Gounder United States 31 1.9k 1.3× 1.1k 1.3× 1.8k 2.6× 298 0.6× 265 0.9× 164 3.7k
Roberto Giardini Italy 32 1.2k 0.8× 661 0.8× 466 0.7× 339 0.7× 374 1.3× 84 3.2k
Virginia Ferraresi Italy 25 1.3k 0.9× 635 0.7× 1.0k 1.5× 370 0.8× 219 0.8× 125 2.4k
Hussein Tawbi United States 24 1.1k 0.8× 739 0.8× 694 1.0× 382 0.8× 112 0.4× 108 2.0k
Dahish Ajarim Saudi Arabia 26 1.4k 0.9× 609 0.7× 376 0.5× 421 0.9× 239 0.8× 88 2.4k
Antonio Maria Grimaldi Italy 22 1.6k 1.1× 654 0.8× 330 0.5× 778 1.6× 191 0.7× 86 2.3k
Angelo Rosolen Italy 31 681 0.5× 907 1.0× 745 1.1× 349 0.7× 127 0.4× 82 2.5k
N. Niederle Germany 28 2.2k 1.6× 727 0.8× 708 1.0× 377 0.8× 496 1.7× 161 4.3k

Countries citing papers authored by Nicholas E. Papadopoulos

Since Specialization
Citations

This map shows the geographic impact of Nicholas E. Papadopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas E. Papadopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas E. Papadopoulos more than expected).

Fields of papers citing papers by Nicholas E. Papadopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas E. Papadopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas E. Papadopoulos. The network helps show where Nicholas E. Papadopoulos may publish in the future.

Co-authorship network of co-authors of Nicholas E. Papadopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas E. Papadopoulos. A scholar is included among the top collaborators of Nicholas E. Papadopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas E. Papadopoulos. Nicholas E. Papadopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kourtis, Stefanos, et al.. (2020). Temporomandibular joint arthritis: possible etiologic factors and arthritis classification.. 12(3). 199–208. 1 indexed citations
2.
Patel, Sapna P., Dae Won Kim, Roland L. Bassett, et al.. (2017). A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunology Immunotherapy. 66(10). 1359–1366. 26 indexed citations
3.
Papadopoulos, Nicholas E., Sapna P. Patel, Kevin B. Kim, et al.. (2014). Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Research. 24(4). 342–348. 12 indexed citations
4.
Davies, Michael A., Patricia S. Fox, Nicholas E. Papadopoulos, et al.. (2012). Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research. 18(4). 1120–1128. 39 indexed citations
5.
Patel, Sapna P., Alexander J. Lazar, Nicholas E. Papadopoulos, et al.. (2012). Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer. 119(4). 799–805. 49 indexed citations
6.
Kim, Kevin B., Víctor G. Prieto, Richard W. Joseph, et al.. (2012). A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Research. 22(4). 294–301. 58 indexed citations
7.
Bedikian, Agop Y., Caimiao Wei, Michelle A. Detry, et al.. (2010). Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. American Journal of Clinical Oncology. 34(6). 603–610. 53 indexed citations
8.
Daud, Adil, Christine Xu, Wen‐Jen Hwu, et al.. (2010). Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemotherapy and Pharmacology. 67(3). 657–666. 17 indexed citations
9.
Homsi, Jade, Agop Y. Bedikian, Nicholas E. Papadopoulos, et al.. (2010). Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma. Melanoma Research. 20(6). 507–510. 65 indexed citations
10.
Bedikian, Agop Y., Marcella M. Johnson, Carla L. Warneke, et al.. (2010). Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?. Melanoma Research. 21(1). 84–90. 7 indexed citations
11.
Papadopoulos, Nicholas E., Agop Y. Bedikian, Sigrid Ring, et al.. (2009). Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. American Journal of Clinical Oncology. 32(5). 509–514. 14 indexed citations
12.
Bedikian, Agop Y., Marcella M. Johnson, Carla L. Warneke, et al.. (2008). Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma. Cancer Investigation. 26(6). 624–633. 57 indexed citations
13.
Kim, Kevin B., Ángela Sanguino, Nicholas E. Papadopoulos, et al.. (2004). Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 100(7). 1478–1483. 62 indexed citations
14.
Kim, Kevin B., et al.. (2004). Pilot study of high‐dose, concurrent biochemotherapy for advanced melanoma. Cancer. 101(3). 596–603. 11 indexed citations
15.
Meric, Funda, Kenneth R. Hess, Datla G. K. Varma, et al.. (2002). Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 95(5). 1120–1126. 87 indexed citations
16.
Eton, Omar, Merrick I. Ross, K Itoh, et al.. (1998). Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.. PubMed. 4(3). 619–27. 23 indexed citations
17.
Patel, Shreyaskumar, M. A. Burgess, Nicholas E. Papadopoulos, et al.. (1997). Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas. Sarcoma. 1(2). 95–97. 18 indexed citations
18.
Patel, Shreyaskumar, Carl Plager, Nicholas E. Papadopoulos, & Robert S. Benjamin. (1995). Myxoid Malignant Fibrous Histiocytoma. American Journal of Clinical Oncology. 18(6). 528–531. 12 indexed citations
19.
Vadhan‐Raj, Saroj, Nicholas E. Papadopoulos, M. A. Burgess, et al.. (1994). Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.. Journal of Clinical Oncology. 12(4). 715–724. 41 indexed citations
20.
Benjamin, Robert S., Sant P. Chawla, C. Humberto Carrasco, et al.. (1990). Primary chemotherapy for osteosarcoma with systemic adriamycin and intra-arterial cisplatin. 42(5). 314–317. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mustafa Beneklı Breakdown of academic impact, for papers by James D. Reimann Breakdown of academic impact, for papers by Mrinal M. Gounder Breakdown of academic impact, for papers by Roberto Giardini Breakdown of academic impact, for papers by Virginia Ferraresi Breakdown of academic impact, for papers by Hussein Tawbi Breakdown of academic impact, for papers by Dahish Ajarim Breakdown of academic impact, for papers by Antonio Maria Grimaldi Breakdown of academic impact, for papers by Angelo Rosolen Breakdown of academic impact, for papers by N. Niederle
Rankless by CCL
2026